Primary Central Nervous System Lymphoma (PCNSL) is a rare invasive extranodal non-
Hodgkin lymphoma, a vast majority of which is Diffuse Large B-Cell Lymphoma (DLBCL). Although
high-dose methotrexate-based immunochemotherapy achieves a high remission rate, the risk of
relapse and related death remains a crucial obstruction to long-term survival. Novel agents for the
treatment of lymphatic malignancies have significantly broadened the horizons of therapeutic options
for PCNSL. The PI3K/AKT/mTOR signaling pathway is one of the most important pathways for Bcell
malignancy growth and survival. Novel therapies that target key components of this pathway have
shown antitumor effects in many B-cell malignancies, including DLBCL. This review will discuss the
aberrant status of the PI3K/AKT/mTOR signaling pathways in PCNSL and the application prospects
of inhibitors in hopes of providing alternative clinical therapeutic strategies and improving prognosis.
Keywords: Primary central nervous system lymphoma, PI3K, AKT, mTOR, inhibitors, targeted therapy.
Grommes C, Pentsova E. Actr-11. phase II study of single agent buparlisib in recurrent/refractory primary (PCNSLl) and secondary cns lymphoma (SCNSL). Neuro-oncol 2016; 18(6): vi3.
Rights & PermissionsPrintExport